Avecho (ASX:AVE) has received a US$3 million (A$4.7 million) payment from pharma heavyweight Sandoz in exchange for the latter’s right to use Avecho’s licence for a CBD capsule sleeping pill.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The term ‘CBD’ refers to the non-psychoactive element within marijuana (the bit that gets you high is called ‘THC’) which has been widely popular in recent years among both medical and recreation markets.
CBD is in just about everything from gummy bears, creams and lotions, roll-on sticks, eyedropper bottles, soft drinks, vand apes. The list goes on.
Whether or not it actually empirically works remains debated, but then again, most people will pay for peace of mind. If they perceive it works, it doesn’t matter.
Thus, the $4.7M from Sandoz.
Worth noting is Avecho’s share price is worth a sixth of a cent. So there’s that. It also has 3B shares on issue – so this payment from Sandoz is, most likely, quite welcome.
But the company stands to make a further US$16M in milestone payments, from Sandoz, should the latter continue progressing Avecho’s CBD capsule product towards commercial sales.
And then there are royalty payments – up to 19% – which makes you wonder if Sandoz truly intends to commercialise.
Or if they truly believe that these products could sell so spectacularly the cut-throat pharmaceutical giant is fine with a 19% royalty. (Sandoz is often accused of patent piracy, and it doesn’t mind a lawsuit.)
More market news
Never-ending: And just like that, Trump’s tariffs are back causing more market chaos
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
“The upfront licensing fee from Sandoz strengthens our financial position, providing the necessary support to accelerate ongoing research and commercial activities,” Avecho CEO Dr. Paul Gavin said.
Let’s hope Sandoz stays interested.
AVE last traded at 6cps.
Join the discussion: See what HotCopper users are saying about AVE and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.